Yaohai Bio-Pharma, a globally leading microbial CRDMO service provider, will showcase its integrated biologics services at the Festival of Biologics 2025. Visit us at Booth #712 to explore end-to-end solutions accelerating drug development from R&D to commercial GMP manufacturing.
Yaohai Bio-Pharma, a leader in microbial CRDMO, is pleased to announce its participation in the Festival of Biologics 2025, a premier global gathering for the biologics community. The event takes place at Messe Basel, Switzerland, from September 30 to October 2, 2025.
Visit Yaohai Bio-Pharma at Booth #712 to discover our comprehensive integrated CRDMO specializing in accelerating biologics programs from early R&D through commercial production, leveraging proven CRDMO expertise in microbial expression systems.
About the Festival of Biologics:
The Festival of Biologics 2025 brings together over 3,000 global leaders – including biotech specialists, startups, academics, regulators, and investors – this flagship event spans the complete biologic therapeutic landscape: antibody therapies, cell & gene therapies, immunotherapies, and biosimilars. It serves as a vital meeting point for innovators, decision-makers, and industry stakeholders shaping the future of biologic medicine.
About Yaohai Bio-Pharma:
Yaohai Bio-Pharma is a CRDMO with over a decade of experience in microbial expression systems. Focused on recombinant proteins, nucleic acid drugs, nanobodies, plasmid DNA, and novel vaccines, Yaohai provides full-lifecycle solutions from R&D to commercial manufacturing. The company is committed to building an open and integrated CRO/CDMO/MAH platform that drives innovation from discovery to commercialization, serving as a trusted partner to global biopharma companies.
